ライフサイエンスコーパス: discontinuation

1 (both grade 3 nephritis leading to treatment discontinuation).

2 slower-than-expected recruitment and funding discontinuation.

3 95% CI=0.56-0.80) in the 6 months following discontinuation.

4 ly SIV-infected rhesus monkeys following ART discontinuation.

5 blinded between randomization and antibiotic discontinuation.

6 ng [(11)C]raclopride PET after antipsychotic discontinuation.

7 A PET before and 6 weeks after antipsychotic discontinuation.

8 ly SIV-infected rhesus monkeys following ART discontinuation.

9 onses, enabling more patients to attempt TKI discontinuation.

10 gender, prior disease status, and treatment discontinuation.

11 r rate for reinitiation of antibiotics after discontinuation.

12 relapse during 12 weeks after antipsychotic discontinuation.

13 t was suboptimal, triggering premature study discontinuation.

14 valproate outperformed placebo for all-cause discontinuation.

15 is uncertain and side effects often lead to discontinuation.

16 one (an infusion reaction) led to treatment discontinuation.

17 after a statin-related adverse event led to discontinuation.

18 showed psychotic relapse after antipsychotic discontinuation.

19 >=3 in 3 [9%]) and did not require treatment discontinuation.

20 nisms underlying relapse after antipsychotic discontinuation.

21 showed BMD recovery 48 weeks following PrEP discontinuation.

22 e and rapidly decreased after bisphosphonate discontinuation.

23 antification in the first 12 weeks after ART discontinuation.

24 dustry trials were more likely to face early discontinuation.

25 ed for characteristics associated with early discontinuation.

26 ithout treatment of the event or osimertinib discontinuation.

27 e of relapse after open-label antidepressant discontinuation.

28 ing on sustained benefits after intervention discontinuation.

29 nd every 16 weeks thereafter until treatment discontinuation.

30 xygen at the time of noninvasive ventilation discontinuation.

31 rrence for at least 15 years after treatment discontinuation.

32 verse events, which led to treatment-regimen discontinuation.

33 rate for re-initiation of antibiotics after discontinuation.

34 elated to glecaprevir/pibrentsavir or led to discontinuation.

35 tes, including durable remissions after drug discontinuation.

36 subject would have SU after 8 weeks of MOIT discontinuation.

37 in Medicaid for 6 months after buprenorphine discontinuation.

38 I was generated at baseline and at treatment discontinuation.

39 in bullous epithelial edema after netarsudil discontinuation.

40 f psychotic relapse related to antipsychotic discontinuation.

41 adversely affect controller status after ART discontinuation.

42 anine aminotransferase that led to treatment discontinuation.

43 L outperformed placebo+LIT/VAL for all-cause discontinuation.

44 spiking fevers remitted, but relapsed after discontinuation.

45 d an adverse event necessitating bedaquiline discontinuation.

46 one from acute myeloid leukaemia after study discontinuation.

47 re used to identify predictors of uptake and discontinuation.

48 use (24 patients [26%]) and antithyroid-drug discontinuation (13 patients [14%]) were the main thyroi

49 of hyperkalemia-related permanent treatment discontinuation (2.3% with finerenone versus 0.8% with p

50 Few adverse events led to discontinuation (26 [7%] of 371).

51 After treatment discontinuation, 36% (24/67), 80% (54/67), and 13% (9/67

52 k ratios compared with placebo for all-cause discontinuation (42 672 participants) ranged from 0.52 (

53 need for antibiotic escalation after initial discontinuation (7.6% vs 4.3%, P = .198).

54 After discontinuation, a greater increase in the BMI standard-

55 imated drug-specific rate ratios for therapy discontinuation adjusted for age, sex, comorbidities, he

56 ulsion (8% versus 1%, p = 0.02) and elective discontinuation (adjusted hazard ratio: 8.75, 95% CI 3.0

57 er when spared or intensified, mainly due to discontinuation after sustained quiescence.

58 ective cohort study of survival and dialysis discontinuation among patients on maintenance dialysis i

59 e patterns and predictors of PrEP uptake and discontinuation among YBMSM in Atlanta, Georgia.

60 Of PrEP initiators, 69% had a first discontinuation and 40% had a final discontinuation duri

61 , between relapsers and non-relapsers before discontinuation and changes due to discontinuation indep

62 patients, mostly driven by physician-guided discontinuation and disruption.

63 nfections, improvement in immune suppression discontinuation and patient-reported quality of life, an

64 bolizer status was associated with tamoxifen discontinuation and prognosis for breast cancer using Co

65 16, and 20 weeks postpartum, family planning discontinuation and/or change, pregnancy incidence, and

66 of adverse events, adverse events leading to discontinuation, and deaths.

67 Time to PrEP uptake, first discontinuation, and final discontinuation were assessed

68 atients with PR/CR at 1 year after nivolumab discontinuation (arm A) and proportion of nivolumab nonr

69 minorities had the same pattern of dialysis discontinuation as whites.

70 The lower discontinuation associated with pembrolizumab should be

71 HBR patients who were event free before DAPT discontinuation at 1 month, favorable safety and effecti

72 Premature treatment discontinuation because of adverse events occurred in 38

73 Discontinuations because of AEs occurred in 10% of patie

74 egarding pooled rates of SVR, adherence, and discontinuation between patients on OST and controls as

75 patients had both a baseline and a treatment discontinuation bone scan (median, 5 doses; interquartil

76 ations were defined as physician-guided DAPT discontinuation, brief interruption (<14 days) or disrup

77 ceptable toxicity, withdrawal of consent, or discontinuation by the investigator.

78 f the study (EOS) in case of early treatment discontinuation/completion.

79 progression, unacceptable toxicity, or other discontinuation criteria were met.

80 e earliest of a thrombotic event, medication discontinuation, death, or end of study on June 30, 2017

81 oportion of patients with adverse events and discontinuations did not differ by randomization arm.

82 ndifferentiated uveitis was a predictor for "discontinuation due to adverse event." Drug retention ti

83 Treatment discontinuation due to adverse events occurred in 13% of

84 Treatment discontinuation due to adverse events was more frequent

85 5% CI = 0.70 to 1.26, p = 0.68), the rate of discontinuation due to adverse events was significantly

86 nsition but associated with a higher risk of discontinuation due to adverse events.

87 ates of response/remission rates and dropout/discontinuation due to adverse events.

88 Evolocumab discontinuation due to AEs occurred in 5.7% of patients.

89 the incidence of adverse events, and time to discontinuation due to an adverse event, assessed in all

90 063) through week 96 was observed in time to discontinuation due to an adverse event.

91 as 3.2-fold higher, and the relative risk of discontinuation due to any adverse event was 59% higher

92 atching were used to identify predictors for discontinuation due to inefficacy and adverse events.

93 otherapy-naive patients was a predictor for "discontinuation due to inefficacy," whereas undifferenti

94 r further biotherapy could be predictive for discontinuation due to inefficacy.

95 Rates of study drug discontinuation due to treatment-emergent adverse events

96 Discontinuations due to adverse events occurred in no pa

97 DOR versus EFV, the treatment difference for discontinuations due to AEs was -3.4%, favoring DOR (95%

98 rators, the relative risk of dyspnea-related discontinuation during follow-up was 6.4-fold higher, th

99 Lack of safety data has led to therapy discontinuation during pregnancy, with health repercussi

100 a first discontinuation and 40% had a final discontinuation during the study period.

101 Using propensity scores for digoxin discontinuation, estimated for each of the 3,499 patient

102 nse, which can be maintained after treatment discontinuation, even without subsequent systemic therap

103 s flare reaction did not result in treatment discontinuation for any patient.

104 ced significantly higher rates of medication discontinuation for diabetes, hypertension, and hyperlip

105 re comparisons were conducted for medication discontinuation for diabetes.

106 Observations were censored at trial discontinuation for reasons other than death or at trial

107 ssociated IRIS was uncommon (4/arm), with no discontinuations for IRIS.

108 There were 2 discontinuations for toxicity (EFV).

109 ivity analysis adjusted for differential IUC discontinuation found similar gVL results.

110 Survival and dialysis discontinuation frequencies among American Indians and A

111 also deteriorated significantly more in the discontinuation group.

112 scores at baseline for the continuation and discontinuation groups, respectively, were 21.4 (SD=9.7)

113 hics, clinical data, timing, and reasons for discontinuation, if occurred, were recorded.

114 adverse events of any grade led to treatment discontinuation in 34 (62%) of 55 patients in the nivolu

115 10, with adverse events leading to treatment discontinuation in 35%, 20%, and 54%, respectively.

116 temporary interruptions in 5, and permanent discontinuation in 4 children.

117 azobactam patients; AEs leading to treatment discontinuation in 5.6% and 8.2%, respectively; and drug

118 We described therapy discontinuation in an unselected population-based cohort

119 ty resulted in more reduced dosing/treatment discontinuation in arm B vs arm C.

120 pitate psychotic relapse after antipsychotic discontinuation in FEP.

121 Treatment-emergent adverse events led to discontinuation in five (5%) patients in the placebo gro

122 mune-related adverse events led to treatment discontinuation in four patients.

123 bound following antiretroviral therapy (ART) discontinuation in HIV-1-infected individuals is believe

124 We evaluated medication discontinuation in IMPROVE-IT (Improved Reduction of Out

125 a, is under-prescribed and has high rates of discontinuation in individuals of African ancestry, due

126 ents receiving placebo, leading to treatment discontinuation in nine (17%) patients treated with apom

127 We would not advise biologic discontinuation in patients on treatment since more than

128 nic stimulation versus 1 week of stimulation discontinuation in patients, and obtained two resting st

129 Adverse events led to discontinuation in six (2%) participants in the bictegra

130 Rejection was the leading AE for study drug discontinuation in the EVR + rTAC group.

131 rious adverse events in five patients and 13 discontinuations in treatment groups because of adverse

132 , factors associated with increased rates of discontinuation included adult age group, percent predic

133 Factors associated with discontinuation included younger age, cannabis use, STI,

134 Although adverse events and study drug discontinuation increased with age, neither was signific

135 rs before discontinuation and changes due to discontinuation independent of relapse.

136 d overdose were high following buprenorphine discontinuation irrespective of treatment duration.

137 The major reason for statin discontinuation is because of the development of statin-

138 itted even without medication, antipsychotic discontinuation is regarded as the most common risk fact

139 t of Erwinia substitution or complete ASNase discontinuation is unknown.

140 Initial de-escalation before discontinuation might improve the success of TFR protoco

141 n, and upon cART initiation, maintenance and discontinuation, mirror those of HIV-1 infection.

142 nd manic/hypomanic/mixed episode (RR-mania), discontinuation, mortality, and individual adverse event

143 and had at least 3 months of follow-up after discontinuation (n = 396).

144 sponses were driven by non-treatment related discontinuations (n = 10 lost to follow-up).

145 Compared with statin treatment discontinuation, nondaily statin dosing lowered total ch

146 ars after PCI, whereas physician-recommended discontinuation occurred more often in anemic patients d

147 These findings do not support discontinuation of ACEI/ARB medications that are clinica

148 Detection of HHV-6 by FA-ME led to discontinuation of acyclovir within 12.0 h in all 12 pat

149 erentiated uveitis may be prone to premature discontinuation of ADA due to adverse events.

150 ices that are less guided by evidence (early discontinuation of antibiotics and extubation attempts)

151 ood of extubation and higher odds of earlier discontinuation of antibiotics.

152 iciency virus type 1 (HIV-1) infection after discontinuation of antiretroviral therapy (ART) is a maj

153 ral rebound and CD4(+) T cell loss after the discontinuation of antiretroviral therapy.

154 Patients with early discontinuation of antithrombotic therapy showed lower b

155 After discontinuation of ART, participants received eight intr

156 Discontinuation of ASNase doses is associated with infer

157 m randomized trials (2001-2020) that studied discontinuation of aspirin 1 to 3 months after PCI with

158 PCI for an acute coronary syndrome, in whom discontinuation of aspirin after 1 to 3 months reduced b

159 Discontinuation of aspirin therapy 1 to 3 months after P

160 Discontinuation of aspirin with continued P2Y(12) inhibi

161 ncreased risk of MACE was not observed after discontinuation of aspirin, including in patients with a

162 ts in group C had adverse events that led to discontinuation of atezolizumab or placebo.

163 After discontinuation of cangrelor/placebo infusion, there wer

164 31 monotherapy prevented viral rebound after discontinuation of cART.

165 ssure (IOP) was elevated above 21 mmHg after discontinuation of corticosteroid eye drops at any follo

166 o relatively rapid transfusion independence, discontinuation of corticosteroids, and hospital dischar

167 to normalization of the platelet count, with discontinuation of daily plasma exchange within 5 days t

168 Physician-guided discontinuation of DAPT appears to be safe, irrespective

169 We examined the frequency of discontinuation of dialysis and used simulations to esti

170 ributable to differences in the frequency of discontinuation of dialysis.

171 eding rates were seen in patients with early discontinuation of dual antiplatelet therapy.

172 of which resolved with drug interruption or discontinuation of either the anti-PD-1 antibody or the

173 the differential diagnosis, and support the discontinuation of empiric antibiotic therapy.

174 Discontinuation of empirical antibiotic therapy followin

175 FA-ME results led to discontinuation of empirical antiviral treatment in 12 p

176 Adverse events led to the discontinuation of fostemsavir in 7% of the patients.

177 eline on the implementation, monitoring, and discontinuation of home oxygen therapy for the pediatric

178 inistration of high-dose corticosteroids and discontinuation of ICIs in severe myocarditis.

179 rism lost their allografts due to TCMR after discontinuation of immunosuppression (56 +/- 3 d).

180 rapy to facilitate the reduction or complete discontinuation of immunosuppression following liver tra

181 Discontinuation of inappropriate antimicrobial therapy i

182 ecified a successful anaesthetic wean as the discontinuation of intravenous anaesthesia without devel

183 action because removal of this factor causes discontinuation of its effect on gene expression.

184 cer treatment, leading to dose reduction and discontinuation of life-saving chemotherapy and a perman

185 the most common causes of dose reduction and discontinuation of life-saving chemotherapy in cancer tr

186 he end of their program cycle that initiated discontinuation of MDA (TF1-9 prevalence <5%), followed

187 remained below the 5% threshold, warranting discontinuation of MDA.

188 Secondary outcome measures included discontinuation of medications for hypertension and hype

189 icial effects that appear to carryover after discontinuation of memantine treatment.

190 improved in most patients within weeks after discontinuation of netarsudil, although 2 patients also

191 epithelial edema improved or resolved after discontinuation of netarsudil.

192 sual acuity stabilized or improved following discontinuation of netarsudil.

193 event that most frequently led to permanent discontinuation of nintedanib was progression of idiopat

194 Notably, discontinuation of OAC after ablation remains relatively

195 G patients had significantly higher rates of discontinuation of oral diabetes medication (70.4% vs 46

196 Five patients (8.8%) required discontinuation of pembrolizumab because of irAEs, all o

197 boratory monitoring per protocol and time to discontinuation of propofol in the setting of triglyceri

198 4 patients had adverse events leading to the discontinuation of rilonacept therapy.

199 On the basis of WHO guidelines, we recommend discontinuation of routine deworming in low-risk areas,

200 Adverse events resulted in discontinuation of SNF472 300 mg, SNF472 600 mg, and pla

201 fficacy outcomes were clinical worsening and discontinuation of supplemental oxygen among patients wh

202 The median time to discontinuation of supplemental oxygen was 5.0 days (95%

203 ssessed a second time either before or after discontinuation of the antidepressant, and followed up f

204 specific clinical scenarios, including early discontinuation of the aspirin component of dual antipla

205 ith objective findings disappeared after the discontinuation of the drug.

206 agement of drug-induced arrhythmias includes discontinuation of the offending medication and followin

207 overcame all of the limitations causing the discontinuation of the other conventional antileishmania

208 gement is largely supportive and may include discontinuation of the specific agent, corticosteroids,

209 cipants reporting adverse events that led to discontinuation of the study drug (36 [1%] of 2694 parti

210 im analysis was done, resulting in premature discontinuation of the study for futility.

211 The incidence of hyperkalemia-related discontinuation of the trial regimen was higher with fin

212 126 [36.5%]) and adverse events that led to discontinuation of the trial treatment (13 [10.4%] vs. 0

213 ed with worse overall outcomes, but usually, discontinuation of therapy was not required.

214 ntensive care unit patients within 7 days of discontinuation of therapy who received ampicillin and t

215 Within 1 week of discontinuation of therapy, each additional day of antib

216 nd mostly mild to moderate, some resulted in discontinuation of therapy.

217 ated liver enzymes that normalized following discontinuation of therapy.

218 Seven patients (3.5%) required discontinuation of these medications due to corrected QT

219 itively associated with an increased risk of discontinuation of treatment (OR 1.37; 95% CI 1.06, 1.76

220 ions may result in a delay or an unnecessary discontinuation of treatment.

221 ebo group, and few adverse events led to the discontinuation of treatment.

222 135/85 mmHg and <170/105 mmHg after a 4-week discontinuation of up to 2 antihypertensive medications

223 e the occurrence of diabetes insipidus after discontinuation of vasopressin infusion among patients w

224 very few reports of diabetes insipidus after discontinuation of vasopressin infusion have been publis

225 occurrence rate of diabetes insipidus after discontinuation of vasopressin infusion was 1.53% among

226 Our findings indicate frequent discontinuations of checkpoint inhibitors at one year.

227 The safety and efficacy of aspirin discontinuation on a background of a P2Y12 inhibitor in

228 We evaluated the effect of MDA discontinuation on TF1-9 prevalence at the district leve

229 ed CRP-guided antibiotic treatment duration (discontinuation once CRP declined by 75% from peak; n =

230 ither regain drug sensitivity upon treatment discontinuation or acquire permanent resistance to thera

231 Rebound can occur after discontinuation or change to alternative refractive trea

232 ents based on the PN panel result, including discontinuation or de-escalation in 48.2% of patients, r

233 ts were mild or moderate and did not require discontinuation or dose reductions.

234 However, inappropriate discontinuation or narrowing of antibiotic treatment cou

235 related to hepatotoxicity frequently lead to discontinuation or non-initiation of 3-hydroxy-3-methylg

236 : treatment policy (regardless of study drug discontinuation or rescue medication) and trial product

237 to model interventions for proper tapering, discontinuation, or follow-up of new start midodrine.

238 t clinical tolerance diminishes over time on discontinuation, or low-dose maintenance, of peanut.

239 rogression, toxicity necessitating treatment discontinuation, patient withdrawal of consent, or study

240 In simulations that assigned discontinuation patterns similar to those found among wh

241 (i.e., rates were not increased with aspirin discontinuation prior to anticoagulation).

242 After the discontinuation PTX with doxorubicin as the substitute,

243 lues and time to relapse after antipsychotic discontinuation (R(2) = 0.518, p = 0.018).

244 erval [CI], 87% to 93%) and pooled treatment discontinuation rate was 7% (95% CI, 4% to 11%).

245 80% to 93%) in PWID and the pooled treatment discontinuation rate was 9% (95% CI, 5% to 15%).

246 Discontinuation rates due to AEs were similar for partic

247 The 6-month discontinuation rates of tamoxifen among poor, intermedi

248 nitial anti-arrhythmic strategy for AF, drug discontinuation rates were high, and many underwent futu

249 Adverse events and treatment discontinuation rates were more common than previously r

250 We measured IUC discontinuation rates with Kaplan-Meier estimates and Co

251 o assess sustained virologic response (SVR), discontinuation rates, adherence, and HCV reinfection in

252 t-effective option only in patients with low discontinuation rates.

253 and US location were associated with higher discontinuation rates.

254 use of lower mTORi dosage has decreased the discontinuation rates.

255 reatment, bisphosphonate continuation versus discontinuation reduced radiographic vertebral fractures

256 if racial and ethnic differences in dialysis discontinuation reflected better health, we conducted a

257 s) versus control or ODT continuation versus discontinuation, reported incident fractures (for trials

258 The seed-based analysis showed that discontinuation resulted in an increased functional conn

259 ezetimibe to statin therapy did not increase discontinuation risk.

260 substantially lower frequencies of dialysis discontinuation than whites in each hospitalization coho

261 Physicians more frequently recommend DAPT discontinuation to anemic patients during the first year

262 rson-level characteristics and time from ART discontinuation to the subsequent reinitiation within 18

263 ted patients had an adverse event leading to discontinuation versus none in the placebo group.

264 35 d vs. 1.04 d for normal; hazard ratio for discontinuation vs. normal, 0.78 [0.73-0.85]; P < 0.001)

265 The cumulative incidence of PEG-ASNase discontinuation was 12.2% +/- 4.6% in AALL0331 and 25.4%

266 The median time to first PrEP discontinuation was 159 days.

267 ose who discontinued OAC, the median time to discontinuation was 6.2 months.

268 Bisphosphonate discontinuation was associated with a rapid decrease in

269 Four-year post-discharge, digoxin discontinuation was associated with significantly higher

270 Therapy discontinuation was defined as a gap between doses beyon

271 Discontinuation was due to lack or loss of efficacy in 7

272 In conclusion, though AE-related study drug discontinuation was higher, an EVR + rTAC regimen repres

273 The risk of discontinuation was highest early in the trial but decre

274 However, early antibiotic discontinuation was more likely (odds ratio, 1.23; 95% C

275 Physician-guided DAPT discontinuation was not associated with increased risk o

276 The strongest predictor of PPI discontinuation was number of days with acid exposure ti

277 uency of adverse events leading to treatment discontinuation was similar in both groups (KdD, 69 [22%

278 e number of patients evaluated for nivolumab discontinuation was too small to assess the value of thi

279 nd absence of rebound iritis with medication discontinuation, was the primary outcome, whereas differ

280 testosterone levels 90 days after treatment discontinuation were 288.4 ng per deciliter in the relug

281 s of follow-up, the probabilities of therapy discontinuation were 49.9% (95% confidence interval, CI

282 rEP uptake, first discontinuation, and final discontinuation were assessed using the Kaplan-Meier met

283 erse health outcomes following buprenorphine discontinuation were compared among patients who were su

284 fore treatment with (223)Ra and at treatment discontinuation were eligible for the study.

285 Reasons for discontinuation were evaluated from randomization throug

286 No drug-related events leading to discontinuation were noted in the linezolid group.

287 Racial and ethnic differences in dialysis discontinuation were present among patients hospitalized

288 remain on treatment; the primary reasons for discontinuation were progressive disease (21%) and AEs (

289 Adverse events that led to study drug discontinuation were reported for no participants in the

290 TEAEs leading to discontinuation were reported in 33 (5%) of 639 atogepan

291 treatment-emergent adverse events leading to discontinuation were reported.

292 No deaths, grade 4 AEs, or AEs leading to discontinuation were reported.

293 ents or events leading to death or treatment discontinuation were reported.

294 Frequent reasons for discontinuation were side effects and low HIV risk perce

295 aBSI at baseline and its change at treatment discontinuation were significant parameters associated w

296 in this cohort of YBMSM was suboptimal, and discontinuations were common despite additional support

297 well as adverse events leading to treatment discontinuation, were less common among zanubrutinib rec

298 ve been associated with premature ticagrelor discontinuation, which may limit any potential advantage

299 , and we compare rebound viral RNA after ART discontinuation with near full-length viral DNA from per

300 es at baseline and their change at treatment discontinuation with overall survival (OS).